Soc. Generale Knock-Out Novo-Nord.../ DE000CL9B3V7 /
| 8/1/2024 8:25:09 AM | Chg.+0.53 | Bid12:25:36 PM | Ask12:25:36 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 18.92EUR | +2.88% | 18.60 Bid Size: 9,000 |
18.61 Ask Size: 9,000 |
NOVO-NORDISK NAM.B D... | 207.1484 DKK | 12/31/2078 | Call |
GlobeNewswire
6/28
SNIPR Biome receives funding for the development of CRISPR-medicines to improve Environmental Enteri...
GlobeNewswire
6/24
Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American ...
GlobeNewswire
6/18
Novo Nordisk announces presentation of data from key semaglutide clinical trials in diabetes, obesit...
GlobeNewswire
6/18
Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for ...
GlobeNewswire
6/17
Veru Reminds Shareholders to Vote in Advance of Tomorrow’s Deadline for 2024 Annual Meeting of Share...
GlobeNewswire
6/13
Aeterna Zentaris Announces Last Patient Last Visit in Pivotal DETECT-Trial for the Diagnosis of Chil...
GlobeNewswire
6/11
Biora Therapeutics Announces Presentation on the BioJet™ Systemic Oral Delivery Platform at the Next...
GlobeNewswire
6/10
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
GlobeNewswire
5/31
Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia...
GlobeNewswire
5/30
Anaqua Annual User Experience Conference to Feature Keynotes from Microsoft, SAP, USPTO, and More
GlobeNewswire
5/15
Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Cl...
GlobeNewswire
5/14
Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Sci...
